Table 1 Baseline characteristics of patients with IPF and treatment of IPF at discharge of the first acute exacerbation.

From: Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation

Characteristics

Patients with recurrence of AE n = 9

Patients without recurrence of AE n = 54

p Value

Age, yr

75.2 ± 4.4

74.6 ± 6.4

0.79

Sex

Male/female

9/0

41/13

0.18

Body mass index

23.3 ± 2.7

21.6 ± 2.7a

0.09

Smoking status

Yes/no

8/1

41/13

0.66

Long-term oxygen therapy

Yes/no

4/9

21/33

0.75

Antifibrotic agent

2

3

0.14

pirfenidone/nintedanib

2/0

2/1

 

Comorbidities

Hypertension

5

29

 > 0.99

Diabetes mellitus

2

21

0.46

Dyslipidemia

2

16

 > 0.99

Atrial fibrillation/flutter

0

4

 > 0.99

Coronary artery disease

1

10

 > 0.99

  1. Values are shown as actual numbers or means ± standard deviation.
  2. an = 45.
  3. AE acute exacerbation, DLco diffusing capacity of lungs for carbon monoxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis.
Back to article page